Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is a clinical-stage biotechnology company with a promising drug candidate pipeline in the Wnt pathway, a critical mediator of tissue repair. With its lead candidate SZN-8141 showing positive preclinical data and approaching potential IND submission in 2H26, strong partnerships with established companies, and a recent research milestone achievement, the company is well-positioned for success in the retinal disease market. Financially, the company has a strong cash position and has shown disciplined expense management. The key question for investors now is whether the positive preclinical results will translate into successful clinical outcomes, which could lead to a significant increase in the company's valuation.

Bears say

Surrozen is heavily reliant on its preclinical drug candidates, SZN-8141, SZN-413, and SZN-8143, which are still in their early stages and have yet to demonstrate their clinical efficacy. With a highly competitive market for retinal disease treatments, it is uncertain if Surrozen's drugs will be able to differentiate and achieve peak commercial revenue. Additionally, the company's current cash reserves and future financing plans may not be sufficient to fund its operations and bring its drugs to market. As a result, we have a negative outlook on Surrozen's stock.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.